DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.88 USD | -0.44% |
|
+0.62% | +7.62% |
| 05-06 | Indian shares set to open higher on Fed rate-cut hopes | RE |
| 05-03 | Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher | MT |
| Sales 2024 * | 279B 3.34B 266B | Sales 2025 * | 299B 3.58B 285B | Capitalization | 1,049B 12.57B 1,001B |
|---|---|---|---|---|---|
| Net income 2024 * | 54.64B 655M 52.15B | Net income 2025 * | 56.74B 680M 54.15B | EV / Sales 2024 * | 3.52 x |
| Net cash position 2024 * | 67.94B 814M 64.85B | Net cash position 2025 * | 107B 1.28B 102B | EV / Sales 2025 * | 3.15 x |
| P/E ratio 2024 * |
19.1
x | P/E ratio 2025 * |
18.4
x | Employees | 25,863 |
| Yield 2024 * |
0.65% | Yield 2025 * |
0.7% | Free-Float | 91.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -0.44% | ||
| 1 week | +0.62% | ||
| Current month | +1.92% | ||
| 1 month | +1.52% | ||
| 3 months | +2.30% | ||
| 6 months | +15.66% | ||
| Current year | +7.62% |
1 week
73.38
75.43
1 month
70.7275.43
Current year
67.1677.72
1 year
53.1277.72
3 years
47.8877.72
5 years
33.3377.72
10 years
28.1377.72
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 01/04/18 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 01/11/20 |
| Chairman | 56 | 17/01/93 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 07/04/86 |
| Chairman | 56 | 17/01/93 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 04/06/07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.69% | 96 M€ | -.--% | - | |
| 1.76% | 11 M€ | -.--% | - | |
| 0.56% | 18 M€ | +6.33% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 74.88 | -0.44% | 164,012 |
| 03/05/24 | 75.21 | +0.58% | 224,293 |
| 02/05/24 | 74.78 | +1.08% | 252,668 |
| 01/05/24 | 73.98 | +0.69% | 116,680 |
| 30/04/24 | 73.47 | -1.28% | 182,060 |
Delayed Quote Nyse, May 06, 2024 at 09:00 pm
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
06/05/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,301
INR
Average target price
6,005
INR
Spread / Average Target
-4.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.52% | 662B | |
| +21.96% | 546B | |
| -5.21% | 359B | |
| +17.02% | 323B | |
| +5.01% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.98% | 167B |
- Stock Market
- Equities
- DRREDDY Stock
- RDY Stock
